Comparison in terms of safety and efficacy between fondaparinux and enoxaparin in acute coronary syndrome

Dr Vinod Kumar; Dr Ritu Bhagat; Dr Shahbaz Khan

Volume : VIII, Issue : VI, June - 2019

Comparison in terms of safety and efficacy between fondaparinux and enoxaparin in acute coronary syndrome

Dr Vinod Kumar, Dr Ritu Bhagat, Dr Shahbaz Khan

Abstract :

Introduction: Cardiovascular disease (CVD) became the most common cause of death worldwide. Today, it accounts for approximately 30% of deaths worldwide including 40% in high income countries and about 28% in low and middle income countries. Coronary artery disease (CAD) is typically defined as a more than 50% stenosis of any epicardial coronary artery. Aim: A study to compare the efficacy and safety of fondaparinux with that of enoxaparin in patients of acute coronary syndrome. Method and Materials: This is a cohort study of one year from Nov. 2014 to Dec. 2015 conducted in GMC Jammu. A total of 180 patients were included in the study. Of these, 90 patients were given fondaparinux and remaining 90 patients were given enoxaparin randomly. Results: In the present study, there was no episode of major bleeding in both the study groups. The difference between the two groups was 1.11%, in terms of minor bleeding, which was not statistically significant. Conclusion: We conclude that fondaparinux is as effective as enoxaparin in the early prevention of major outcomes in acute coronary syndrome. In addition, fondaparinux appears to be safe in terms of bleeding risk than enoxaparin, a benefit which may lead to long–term reduction in ischemic complications and death.